Stockwatch: Bullishness Or Belligerence At Roche And Biogen?
Biogen And Roche’s First-Quarter Results Make Unusual Bedfellows
After only two weeks of the first-quarter 2020 earnings season for biopharmaceutical companies, the tempo of the announcements seems already to have been defined. Unless companies are exposed to, on the one hand, medical devices, or on the other, consumer health or diagnostics, the impact of the coronavirus pandemic on pure play biopharmaceutical companies has so far been marginal.
